Celldex's experimental hives treatment meets endpoints but raises anaphylaxis concerns
In two late-stage trials, Celldex's barzolvolimab achieved its primary goal for chronic hives, but two cases of life-threatening allergic reactions after dosing have cast a shadow. The company now faces scrutiny over the drug's safety profile as it moves toward regulatory submission.
The late-stage results mark a pivotal step for Celldex’s candidate, which met its primary efficacy endpoint in chronic hives—a condition marked by recurring, painful welts. However, the emergence of two anaphylaxis cases after dosing introduces a serious safety question that regulators will weigh closely. These events could complicate the path to submission, as risk-benefit assessments for chronic, non-life-threatening conditions demand high safety margins.
The company now faces the dual challenge of demonstrating durable symptom relief while addressing the mechanism behind these severe allergic reactions. No further details on patient demographics, dosing schedules, or reaction timing were disclosed, leaving the full risk profile unresolved until full trial data are reviewed.
If approved, this therapy could offer a new option for patients with chronic hives who fail existing treatments, potentially improving quality of life. Yet the anaphylaxis signal may prompt stricter monitoring requirements or restrict use to certain populations, limiting real-world access. Physicians and patients will weigh efficacy against rare but severe risks, and payers may demand robust safety evidence before coverage decisions. The outcome could influence how similar biologics are evaluated for allergic conditions.